Bisphosphonate Therapy for Osteogenesis Imperfecta
| Status: | Archived |
|---|---|
| Conditions: | Osteoporosis, Orthopedic |
| Therapuetic Areas: | Rheumatology, Orthopedics / Podiatry |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
The study is designed to evaluate the efficacy and safety of "Bisphosphonate Therapy for
Osteogenesis Imperfecta (OI)." We, the researchers at Indiana University School of Medicine,
are characterizing the changes effected by oral bisphosphonate therapy and comparing them to
a regimen of intravenous bisphosphonate therapy in a group of children with OI and also in
children with other disorders that result in low bone mass and fractures.
The study is designed to evaluate the efficacy and safety of "Bisphosphonate Therapy for
Osteogenesis Imperfecta (OI)." OI is an inherited disorder of collagen synthesis. Collagen
is the major structural protein of the matrix of tendons, skin, and bones. Affected persons
have low bone mineral density (and experience multiple fractures and progressive bony
deformity). In its most severe form, the disorder is lethal in infancy. We plan to
characterize the changes effected by oral bisphosphonate therapy and compare them to a
regimen of intravenous bisphosphonate therapy in a group of children with OI.
Additionally, we have begun to treat patients with OI and other conditions of low bone
mineralization for age who are not eligible for the standard protocol (too young, history of
abdominal pain, etc.) with bisphosphonate. We also plan to screen the parents and siblings
of our patients diagnosed with osteogenesis imperfecta, in order to determine if they also
have osteoporosis.
We found this trial at
1
site
Click here to add this to my saved trials
